Healthcare company Lincoln Pharmaceuticals reported a marginal increase in profit at ₹11.63 crore in the fourth quarter ended March 31, 2026, compared to ₹11.57 crore in the same period of the previous year. According to the company's statement, revenue from operations rose by 13.5% to ₹183.08 crore in the quarter under review, compared to ₹161.30 crore reported in the last quarter of FY25. As per Devdiscourse, the company announced a slight increase in profit to ₹11.63 crore for the fourth quarter ending in March 2026.
For the full 2025-26 fiscal year, Lincoln Pharma reported over 6% growth in consolidated net profit to ₹87.89 crore compared to the net profit of ₹82.35 crore in FY25. Revenue from operations for FY26 was reported at ₹704.48 crore as compared to revenue of ₹645.71 crore reported in FY25, registering a growth of 9.10% year-on-year. According to Devdiscourse, the company saw a consolidated net profit rise of over 6% to ₹87.89 crore for the entire fiscal year 2025-26.
The company's board has recommended a dividend of 18%, ₹1.80 per share on the face value of ₹10 per share for the FY 2025-26. This dividend declaration reflects the company's commitment to returning value to shareholders while maintaining growth investments. As per The Financial Express, the dividend announcement was made on May 28, 2026, following the board's approval of audited financial results for the quarter and year ended March 31, 2026. The company has also proposed an 18% dividend, equating to ₹1.80 per share for the fiscal year 2025-26.
Despite the positive quarterly results, Lincoln Pharmaceuticals shares declined 16.67% to ₹631.90 as of May 29, 2026, reflecting market volatility. The stock traded between a 52-week high of ₹770.00 and a 52-week low of ₹439.95. According to The Financial Express, the company's market capitalization stands at ₹1,259.37 crore as of May 29, 2026. The stock's performance shows mixed signals with a 14.43% gain over the past year, though it has declined 2.75% in the last month. The company's P/E ratio stands at 14.34 with a dividend yield of 0.29%.
Looking ahead, Lincoln Pharmaceuticals has set an ambitious target of achieving ₹1,000 crore revenue within the next three years. According to the company's statement, this growth strategy is driven by business expansion into high-value product lines and entry into new markets, positioning the company for significant scale expansion in the coming years. With aspirations to hit ₹1,000 crore in revenue within three years, Lincoln Pharmaceuticals plans to expand its business into high-value product lines and tap into new markets, as reported by Devdiscourse.
